DHL Group has announced the expansion of its life sciences arm—DHL Health Logistics—with the development of a €10 million Pharmaceutical Hub in Singapore. This investment bolsters regional Life Sciences and Healthcare (LSHC) infrastructure.
Located near Tuas Biomedical Park, this facility reinforces Singapore's position as a strategic hub for Asia-Pacific, offering efficient connectivity to Changi Airport and Tuas Mega Port. These investments are part of a broader commitment to invest €500 million into regional health logistics by 2030, supporting resilience in global healthcare supply chains.
The demand for specialised healthcare logistics is rising, driven by global health challenges, an ageing population, and the development of advanced therapies. In Singapore, the biomedical sector produces goods valued at nearly S$38 billion for global markets. The industry requires a health logistics infrastructure capable of accommodating the increasing volume and complexity of life-saving products distributed from regional hubs to the rest of the world.
DHL leverages an extensive global network spanning over 220 countries and territories to facilitate seamless international logistics. Through DHL Health Logistics and its services, the group utilises dedicated healthcare hubs and warehouses within a GDP-compliant infrastructure. This allows the group to support the global healthcare ecosystem with a combination of high-capacity transport and local handling.
